10x Genomics Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) reported Q2 2024 financial results with revenue of $153.1 million, a 4% increase year-over-year. The company began shipping Xenium Prime 5K, featuring enhanced chemistry and integrated multimodal cell segmentation. Gross margin remained flat at 68%, while operating expenses decreased by 10% to $146.0 million. The operating loss narrowed to $41.7 million from $63.4 million in the prior year period. Net loss improved to $37.9 million compared to $62.4 million last year. Cash and equivalents stood at $380.1 million as of June 30, 2024. 10x Genomics updated its full-year 2024 revenue guidance to $640-$660 million, representing 3-7% growth over 2023.

Positive

• Revenue increased by 4% year-over-year to $153.1 million
• Operating loss improved from $63.4 million to $41.7 million
• Net loss decreased from $62.4 million to $37.9 million
• Operating expenses reduced by 10% to $146.0 million

Negative

• Full-year 2024 revenue guidance lowered from $670-$690 million to $640-$660 million
• Gross margin remained flat at 68% year-over-year

Insights

Financial Analyst

10x Genomics' Q2 2024 results show mixed signals. Revenue grew 4% year-over-year to $153.1 million, primarily driven by stronger consumables sales. However, the company lowered its full-year guidance, now expecting revenue between $640 million and $660 million, down from the previous $670 million to $690 million range.

Positively, the company reduced its operating loss to $41.7 million from $63.4 million in Q2 2023, mainly due to a 10% decrease in operating expenses. The gross margin remained stable at 68%. With $380.1 million in cash and marketable securities, 10x Genomics maintains a solid financial position to navigate current challenges.

Investors should note the company's ability to grow revenue in a challenging macro environment, but also be cautious about the lowered guidance, which suggests ongoing headwinds in the life sciences tools sector.

Market Research Analyst

The launch of Xenium Prime 5K and the Garvan Institute's selection of Chromium GEM-X for its TenK10K project highlight 10x Genomics' continued innovation and market relevance. These developments suggest potential for future growth in the single cell and spatial biology markets.

However, the lowered full-year guidance indicates persistent market challenges. The revised 3% to 7% growth projection for 2024 is modest for a company in the high-growth life sciences sector. This could reflect broader industry headwinds, including potential budget constraints among academic and biopharma customers.

The strong demand for spatial and single cell consumables is a positive indicator of the company's product adoption. However, investors should monitor how 10x Genomics navigates the evolving commercial landscape and executes its strategy to drive long-term growth in a competitive market.

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024.

Recent Highlights

• Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.
• Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated multimodal cell segmentation.
• Announced that the Garvan Institute of Medical Research selected Chromium GEM-X for its new TenK10K project, which intends to map 50 million human cells to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer.

"While it's a challenging macro environment, we saw strong demand for spatial and single cell consumables this quarter, fueled by significant product launches earlier this year," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We remain confident in the strength, differentiation and long-term potential of our platforms as we evolve our commercial organization and continue to execute our strategy."

Second Quarter 2024 Financial Results

Revenue was $153.1 million for the second quarter of 2024, a 4% increase from $146.8 million for the corresponding prior year period.

Gross margin was flat year over year at 68%.

Operating expenses were $146.0 million for the second quarter of 2024, a 10% decrease from $163.0 million for the corresponding prior year period. This decrease was primarily driven by lower personnel expenses, including stock-based compensation expense, and a decrease in laboratory materials and supplies.

Operating loss was $41.7 million for the second quarter of 2024, as compared to $63.4 million for the corresponding prior year period. Operating loss includes $38.5 million of stock-based compensation for the second quarter of 2024, as compared to $45.7 million of stock-based compensation for the corresponding prior year period.

Net loss was $37.9 million for the second quarter of 2024, as compared to a net loss of $62.4 million for the corresponding prior year period.

Cash and cash equivalents and marketable securities were $380.1 million as of June 30, 2024.

2024 Financial Guidance

10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in the range of $640 million to $660 million versus a prior range of $670 million to $690 million. The updated range represents 3% to 7% growth over full year 2023 revenue.

Webcast and Conference Call Information

10x Genomics will host a conference call to discuss the second quarter 2024 financial results, business developments and outlook after market close on Thursday, August 8, 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s product momentum, potential, organization, strategy, demand, progress and launches, our expected performance advantages and benefits of using our products and services, customer usage and adoption of our products and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and the company's 10-Q for the quarter ended March 31, 2024 to be filed with the Securities and Exchange Commission (SEC) and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, our website (https://www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

 

10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Revenue (1)	$         153,104		$         146,819		$         294,110		$         281,104
Cost of revenue (2)	48,884		47,207		96,976		83,102
Gross profit	104,220		99,612		197,134		198,002
Operating expenses:
Research and development (2)	62,918		71,460		131,556		138,558
Selling, general and administrative (2)	83,039		91,510		168,813		174,790
Total operating expenses	145,957		162,970		300,369		313,348
Loss from operations	(41,737)		(63,358)		(103,235)		(115,346)
Other income (expense):
Interest income	4,715		4,100		9,451		7,969
Interest expense	(1)		(5)		(2)		(24)
Other expense, net	(56)		(1,504)		(1,096)		(3,020)
Total other income	4,658		2,591		8,353		4,925
Loss before provision for income taxes	(37,079)		(60,767)		(94,882)		(110,421)
Provision for income taxes	818		1,647		2,964		2,740
Net loss	$          (37,897)		$          (62,414)		$          (97,846)		$       (113,161)
Net loss per share, basic and diluted	$              (0.32)		$              (0.53)		$              (0.82)		$              (0.97)
Weighted-average shares of common stock used in     computing net loss per share, basic and diluted	120,066,972		116,707,672		119,461,485		116,166,776

(1)                 The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Instruments
Chromium	$              8,792		$           12,859		$           16,642		$           24,485
Spatial	15,060		18,096		32,663		25,646
Total instruments revenue	23,852		30,955		49,305		50,131
Consumables
Chromium	94,108		100,794		178,035		201,890
Spatial	29,254		11,694		55,662		22,976
Total consumables revenue	123,362		112,488		233,697		224,866
Services	5,890		3,376		11,108		6,107
Total revenue	$         153,104		$         146,819		$         294,110		$         281,104

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Americas
United States	$           89,672		$           88,394		$         165,309		$         164,675
Americas (excluding United States)	3,419		3,149		7,412		5,664
Total Americas	93,091		91,543		172,721		170,339
Europe, Middle East and Africa	37,362		31,246		72,083		59,668
Asia-Pacific
China	13,738		12,755		27,662		26,786
Asia-Pacific (excluding China)	8,913		11,275		21,644		24,311
Total Asia-Pacific	22,651		24,030		49,306		51,097
Total Revenue	$         153,104		$         146,819		$         294,110		$         281,104

(2)                 Includes stock-based compensation expense as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
Cost of revenue	$              2,247		$              1,835		$              4,280		$              3,296
Research and development	17,862		19,560		34,750		37,340
Selling, general and administrative	18,383		24,301		35,591		47,161
Total stock-based compensation expense	$           38,492		$           45,696		$           74,621		$           87,797

 

10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
	June 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$         379,824		$         359,284
Marketable securities	269		29,411
Accounts receivable, net	91,178		114,832
Inventory	88,272		73,706
Prepaid expenses and other current assets	19,612		18,789
Total current assets	579,155		596,022
Property and equipment, net	263,285		279,571
Operating lease right-of-use assets	60,872		65,361
Goodwill	4,511		4,511
Intangible assets, net	16,658		16,616
Other noncurrent assets	5,187		3,062
Total assets	$         929,668		$         965,143
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$           21,248		$           15,738
Accrued compensation and related benefits	20,078		30,105
Accrued expenses and other current liabilities	42,437		56,648
Deferred revenue	16,436		13,150
Operating lease liabilities	10,820		11,521
Total current liabilities	111,019		127,162
Operating lease liabilities, noncurrent	78,662		83,849
Deferred revenue, noncurrent	11,358		8,814
Other noncurrent liabilities	4,571		4,275
Total liabilities	205,610		224,100
Commitments and contingencies
Stockholders' equity:
Preferred stock	—		—
Common stock	2		2
Additional paid-in capital	2,106,752		2,025,890
Accumulated deficit	(1,382,266)		(1,284,420)
Accumulated other comprehensive loss	(430)		(429)
Total stockholders' equity	724,058		741,043
Total liabilities and stockholders' equity	$         929,668		$         965,143

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-second-quarter-2024-financial-results-302218347.html

SOURCE 10x Genomics, Inc.

FAQ

What was 10x Genomics' revenue for Q2 2024?

10x Genomics reported revenue of $153.1 million for Q2 2024, a 4% increase compared to the same period in 2023.

How did 10x Genomics' (TXG) operating loss change in Q2 2024?

10x Genomics' operating loss improved to $41.7 million in Q2 2024, compared to $63.4 million in the corresponding prior year period.

What is 10x Genomics' (TXG) updated revenue guidance for full-year 2024?

10x Genomics updated its full-year 2024 revenue guidance to a range of $640 million to $660 million, representing 3% to 7% growth over 2023.

What new product did 10x Genomics (TXG) begin shipping in Q2 2024?

10x Genomics began shipping Xenium Prime 5K, which measures 5,000 genes and features enhanced chemistry for improved sensitivity, specificity, and spatial fidelity.